What We're Reading: Page 97
Industry reads hand-picked by our editors
Feb 16, 2023
-
The Wall Street Journal
Health Startups Offer Diabetes Drugs Like Ozempic for Weight Loss With Little Oversight
-
MIT Technology Review
AI is dreaming up drugs that no one has ever seen. Now we’ve got to see if they work.
-
Nature
How a pioneering diabetes drug offers hope for preventing autoimmune disorders
-
ProPublica
Steak Dinners, Sales Reps and Risky Procedures: Inside the Big Business of Clogged Arteries
Feb 15, 2023
Feb 14, 2023
-
Financial Times
Women’s health ‘missing out’ because of male-dominated investment
-
The Wall Street Journal
Collecting Pharma’s Scraps Can Pay Off for This Biotech
-
The New York Times
Binge Drinking May Be Curbed With a Pill
-
C&EN
In the chemical industry, a tentative journey to ‘point and click’
Feb 13, 2023
Feb 10, 2023
-
NBC News
Fungal infections are becoming more common. Why isn’t there a vaccine?
-
Bloomberg
Advent, CVC Are Among Suitors for €3 Billion Viatris OTC Assets
-
The Wall Street Journal
Layoffs and Shutdowns Hit Biotech Industry in U-Turn
-
In The Pipeline
Molnupiravir Mutations in the Wild
Feb 09, 2023
-
The Wall Street Journal
Pfizer, Novartis, Merck Executives Say They Are Hunting for Deals Again
-
The New Yorker
The Promise of a New Alzheimer’s Drug
-
Reuters
Why Europe’s drug shortages may get worse
-
Science News
Disorder or difference? Autism researchers face off over field’s terminology
Feb 08, 2023
-
Bloomberg
Nestlé’s $6,000 Peanut Allergy Pill Has Been a Dud
-
Disorder or difference? Autism researchers face off over field’s terminology
-
Scientific American
COVID Rebound Can Happen Even without Paxlovid
-
Healthcare Dive
CVS buys Oak Street Health for $10.6B
Previous
